Bio-Rad's Q2 Revenues Rise 12 Percent

Its revenues rose for both the Life Sciences and Clinical Diagnostics segments, but the firm missed bottom-line estimates on increased SG&A expenses and a higher tax rate.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories